Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen to present new osteoporosis drug data at ASBMR 2016

Amgen to present new osteoporosis drug data at ASBMR 2016

9th September 2016

Amgen will be attending this year's American Society for Bone and Mineral Research (ASBMR) annual meeting, where it will share its latest osteoporosis research insights.

A total of 19 abstracts are planned for the conference in Atlanta from September 16th to 19th, including data from multiple studies covering its investigational agent romosozumab and the established therapy Prolia.

Its presentation of data from the phase III FRAME study of romosozumab has been awarded the 2016 ASBMR Most Outstanding Clinical Abstract Award, which is given to the lead investigator of the highest-ranking abstract submitted for presentation at the meeting.

Meanwhile, the Prolia presentations will include analyses from the three-year FREEDOM trial and its seven-year extension, showing the long-term efficacy and safety of the drug in postmenopausal women with osteoporosis.

Real-world data will also show long-term persistence rates for Prolia and other osteoporosis therapies among postmenopausal women.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "The breadth and depth of clinical and real-world data we're presenting at ASBMR demonstrates our commitment to finding potential options for patients with osteoporosis."

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.ADNFCR-8000103-ID-801824964-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.